Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 2/2014

01-06-2014 | Original Article

Neurological presentations of the antiphospholipid syndrome: three illustrative cases

Authors: Ch. De Maeseneire, M. C. Duray, M. P. Rutgers, M. Gille

Published in: Acta Neurologica Belgica | Issue 2/2014

Login to get access

Abstract

The antiphospholipid syndrome (APS) is defined by the association of high titers of antiphospholipid antibodies (aPLs) with thrombotic events and/or obstetrical problems. APS can be isolated or associated with immune system diseases. Several central nervous system (CNS) manifestations have been reported in APS, but are still not included in the international diagnostic criteria. We present here three cases of APS revealed by CNS manifestations. The first patient had a primary APS with stroke, dementia, epilepsy and the “so-called” Liebman–Sacks disease, a subacute thrombotic non-bacterial valvulopathy. The second one developed a primary APS with a Sneddon syndrome, while the third case is a neurolupus-associated APS with subacute encephalopathy, chorea, stroke, and epilepsy. The pathogenesis of the APS is related to both prothrombotic and immunologic effects of the aPLs. Long-term anticoagulation by low-weight heparin or warfarin is currently recommended in APS. We propose to search the presence of aPLs in any case of young adults’ stroke, unexplained dementia, and acquired chorea.
Literature
1.
Hughes G, Harris NN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13(3):486–489PubMed
2.
Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306PubMedCrossRef
3.
Urbanus RT, Siegerink B, Roest M et al (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol 8(11):998–1005PubMedCrossRef
4.
Bodiguel E (1992) Antiphospholipid antibodies and the central nervous system. Rev Neurol 148(11):655–662PubMed
5.
Morrissette N, Gorman T (2010) Antiphospholipid syndrome and homozygous factor V Leiden mutation in a young patient with Libeman–sacks endocarditis and stroke. Am J Med 123(9):e3–e4CrossRef
6.
Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033–1044PubMedCrossRef
7.
Cervera R, Bucciarelli S, Plasín MA et al (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 32(3–4):240–245PubMedCrossRef
8.
Asherson RA, Khamashta MA, Gil A et al (1989) Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 86:391–399PubMedCrossRef
9.
Briley DP, Coull BM, Goodnight SH Jr (1989) Neurological disease associated with antiphospholipid syndrome. Ann Neurol 25:221–227PubMedCrossRef
10.
Krause I, Lev S, Fraser A et al (2005) Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 64(10):1490–1493PubMedCentralPubMedCrossRef
11.
Brey R (2005) Antiphospholipid syndrome in young adults with stroke. J Thromb Thrombolysis 20(2):105–112PubMedCrossRef
12.
13.
Ferro JM, Canhão P, Stam J et al (2004) Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke 35:664–670PubMedCrossRef
14.
Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46(4):1019–1027PubMedCrossRef
15.
Gomez-Puerta JA, Cervera R, Calvo LM et al (2005) Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology 44:95–99PubMedCrossRef
16.
Marinho JL, Piovesan EJ, Pereira Leite Neto M et al (2007) Clinical, neurovascular and neuropathological features in Sneddon’s syndrome. Arq Neuropsiquiatr 65(2B):390–395PubMedCrossRef
17.
Montané de la Roque P, Michard JF, Pinganaud-Shrestha C et al (2006) Syndrome démentiel révélant un syndrome de Sneddon. Rev Med Interne 27:156–164CrossRef
18.
Uthman IW, Khamashta MA (2006) Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol 33:12
19.
Maamar M, Rahmani M, Aidi S et al (2007) Sneddon’s syndrome: 15 cases with cerebral angiography. Revue Neurologique 163(8–9):809–816PubMedCrossRef
20.
Dutra L, Braga-Neto P, Pedroso JL et al (2012) Sneddon’s syndrome: case report and review of its relationship with antiphospholipid syndrome. Einstein 10(2):230–232PubMedCrossRef
21.
22.
Stockhammer G, Stephan R, Felber R et al (1993) Sneddon’s syndrome. Diagnostic by skin biopsy and RMI in 17 patients. Stroke 24:685–690PubMedCrossRef
23.
Francès C, Papo T, Wechsler B et al (1999) Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 78(4):209–219CrossRef
24.
Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58(8):1214–1220PubMedCrossRef
25.
Joseph FG, Lammie GA, Scolding NJ et al (2007) CNS lupus: a study of 41 patients. Neurology 69:644–654PubMedCrossRef
26.
Spinosa MJ, Bandeira M, Liberalesso PB et al (2007) Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system. Arq Neuropsiquiatr 65(2B):433–439PubMedCrossRef
27.
Asherson RA, Derksen RH, Harris EN et al (1987) Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 16(4):253–259PubMedCrossRef
28.
Baizabal-Carvallo J, Alonso-Juarez M, Koslowski M (2011) Chorea in systemic lupus erythematosus. J Clin Rheumatol 17(2):69–72PubMedCrossRef
29.
Cervera R, Asherson RA, Font J et al (1997) Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 76(3):203–212CrossRef
30.
31.
Avcin T, Benseler SM, Tyrrell PN et al (2008) A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 59(2):206–213PubMedCrossRef
32.
Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56(7):2382–2391PubMedCrossRef
33.
Cervera R, Khamashta MA, Shoenfeld Y et al (2009) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 68(9):1428–1432PubMedCrossRef
34.
Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033–1044PubMedCrossRef
35.
Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295(9):1050–1057PubMedCrossRef
36.
Crowther MA, Ginsberg JS, Julian J et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. NEJM 349:1133–1138PubMedCrossRef
37.
Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853PubMedCrossRef
38.
Saadoun D, Piette J-C, Wahl D et al (2012) Management of antiphospholipid syndrome. Rev Med Interne 33(4):217–222PubMedCrossRef
39.
Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355–376CrossRef
40.
Erkan D, Cervera R, Asherson RA (2003) Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 48(12):3320–3327PubMedCrossRef
41.
Statkute L, Traynor A, Oyama Y et al (2005) Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 106(8):2700–2709PubMedCrossRef
42.
Erkan D, Vega J, Ramón G et al (2013) A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65(2):464–471PubMedCrossRef
43.
Arachchillage DJ, Cohen H (2013) Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 15(6):331PubMedCrossRef
44.
Comarmond C, Cacoub P (2013) Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 12(7):752–757
45.
Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA et al (2012) Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep 14(1):87–94PubMedCrossRef
Metadata
Title
Neurological presentations of the antiphospholipid syndrome: three illustrative cases
Authors
Ch. De Maeseneire
M. C. Duray
M. P. Rutgers
M. Gille
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Acta Neurologica Belgica / Issue 2/2014
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-013-0275-6

Other articles of this Issue 2/2014

Acta Neurologica Belgica 2/2014 Go to the issue

Original Article

Quantitative and qualitative evaluation tool in planning stroke treatment strategies: the “Safe implementation of treatments in stroke Monitoring Study (SITS MOST)” registry

Review Article

Upper airway imaging in sleep-disordered breathing

Letter to the Editor

Plus–minus lid syndrome caused by thalamic hematoma

Letter to the Editor

Rupture of the middle cerebral artery aneurysm as a presenting symptom of late-onset Pompe disease in an adult with a novel GAA gene mutation

Original Article

Clinical characteristics of acute lacunar stroke in women: emphasis on gender differences

Original Article

Delayed intravenous thrombolysis based on MRI mismatch in posterior circulation stroke